China gave on Wednesday the green light for the use of Brii Biosciences’ antibody cocktail treatment for COVID-19, in the wake of an epidemic recovery and the appearance of the new Omicron variant.
A statement by Brii on Thursday said final results from a Phase III clinical trial showed an 80% reduction of hospitalization and deaths in non-hospitalized COVID-19 patients at high risk of developing severe disease.
The treatment targets patients already affected by the virus, but Brii is also studying using the medicine as prevention of COVID-19.
China reported 83 new infections nationwide on Thursday.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.